Form 8-K - Current report:
SEC Accession No. 0001104659-25-039799
Filing Date
2025-04-28
Accepted
2025-04-28 08:15:56
Documents
15
Period of Report
2025-04-23
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513158d1_8k.htm   iXBRL 8-K 34079
2 EXHIBIT 99.1 tm2513158d1_ex99-1.htm EX-99.1 8766
6 GRAPHIC tm2513158d1_ex99-1img001.jpg GRAPHIC 9871
  Complete submission text file 0001104659-25-039799.txt   238849

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avbp-20250423.xsd EX-101.SCH 3014
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20250423_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20250423_pre.xml EX-101.PRE 22358
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2513158d1_8k_htm.xml XML 3815
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 25876032
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)